RIGHT. ON TIME. — India's Trusted Nuclear Medicine, Radiotherapy & Oncology Partner for the last 40 years

+91 11 4077 6666 saxsons@saxsons.com

24 Jul 2026Peer-ReviewedPubMedResearch ArticleEuropean urology · 2026

Five-Year Patient-Reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?

Blanchard P, Sighinolfi C, Terlizzi M, Rocco B.

Read on PubMed →doi:10.1016/j.eururo.2026.07.023 →

Identifiers

PubMed ID: 42498607

DOI: 10.1016/j.eururo.2026.07.023

Radar topics

Related in the same topic

International journal of clinical oncology · 2026

Clinical indications and implications of metastasis-directed therapy and primary-site treatment in metastatic urothelial carcinoma.

Physical and engineering sciences in medicine · 2026

The use of Perspex-based devices in patient specific quality assurance of Acuros XB plans.

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: Research Summary.

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2026

Long-term control after stereotactic body radiotherapy for perineal recurrence of prostate cancer after radical prostatectomy and radiotherapy: A case report and review of the literature.

International journal of radiation oncology, biology, physics · 2026

Phase I/II Trial of Durvalumab plus Tremelimumab and Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma.

Search all papers →More SBRT delivery research →